Atrial Fibrillation Recurrence After Maze and Mitral Valve Surgery

Atrial fibrillation is the most common sustained arrhythmia encountered in cardiac surgical practice, and its prevalence climbs steeply among patients referred for mitral valve surgery. The Cox-Maze procedure, introduced in the late 1980s, remains the most effective surgical intervention for restoring sinus rhythm in this population, with long-term freedom from atrial fibrillation reported in roughly 70 to 90 percent of patients at five years. Despite those encouraging results, recurrent atrial fibrillation after an apparently successful maze procedure is a well-recognised clinical problem that complicates postoperative management, increases thromboembolic risk, and diminishes the long-term gains of valve repair or replacement.

In Australia, where rheumatic heart disease continues to affect Aboriginal and Torres Strait Islander communities at rates well above the national average, mitral valve surgery is performed in a uniquely diverse patient population. Cardiac surgical units at The Alfred in Melbourne, Royal Prince Alfred in Sydney, and The Prince Charles Hospital in Brisbane encounter both degenerative and rheumatic mitral disease, and the decision to add a maze procedure often reflects local expertise and resource availability as much as clinical indication. Understanding the drivers of recurrent arrhythmia in this setting is central to counselling patients, planning follow-up, and allocating outpatient cardiology resources in a health system that already faces pressure on elective waiting lists.

The surgical maze procedure in context

The original cut-and-sew Cox-Maze III operation has largely been replaced by alternative energy sources, including radiofrequency, cryothermal, and more recently pulsed-field ablation, which create linear lesions in left and right atrial tissue to interrupt the re-entrant circuits that sustain atrial fibrillation. Most contemporary series use a biatrial lesion set, though a left-atrial-only approach is favoured by some surgeons when sinus rhythm restoration is the primary aim. In patients undergoing mitral valve surgery, the addition of a maze procedure adds roughly 15 to 25 minutes of operative time and, in experienced hands, does not substantially increase perioperative morbidity.

Australian and New Zealand surgeons have contributed meaningfully to the evidence base, with the Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) registry capturing outcomes from most public and private units across the country. Registry analyses have shown that the maze procedure is offered in around 40 to 50 percent of mitral valve operations, with considerable inter-hospital variation. Recent work published in Journal of Arrhythmia has emphasised that lesion completeness, rather than energy source, is the principal determinant of early and mid-term rhythm outcomes, a finding that resonates with Australian data and supports ongoing quality assurance in surgical ablation training.

Why AF returns after an apparently successful ablation

Recurrence of atrial fibrillation after the maze procedure is rarely attributable to a single mechanism. Incomplete transmural lesions leave gaps that allow macro-re-entry circuits to reform, particularly along the mitral isthmus and the roof of the left atrium. Beyond lesion set, progressive atrial cardiomyopathy driven by ongoing valvular disease, ventricular dysfunction, or pulmonary hypertension creates an arrhythmogenic substrate that is incompletely addressed by surgical ablation at the time of valve surgery. Postoperative inflammation, adrenergic activation, and atrial ischaemia in the early days after cardiopulmonary bypass can also trigger transient arrhythmias that later evolve into persistent atrial fibrillation.

Exploring exercise testing and ambulatory monitoring during the first postoperative year has demonstrated that brief, asymptomatic bursts of atrial fibrillation are far more common than the binary success or failure classification used in older trials. In practice, many Australian patients who are considered to be in sinus rhythm at routine clinic review actually have paroxysmal episodes that are only detected on prolonged monitoring. This distinction matters because recurrent episodes, even if brief, are associated with ongoing stroke risk and reduced quality of life, and they often prompt reconsideration of long-term anticoagulation strategies.

Identifying patients at higher risk of recurrence

Several preoperative and intraoperative variables have consistently predicted recurrent atrial fibrillation after maze procedures combined with mitral valve surgery. Left atrial diameter greater than 55 mm, longstanding persistent atrial fibrillation of more than five years' duration, advanced age, and reduced left ventricular ejection fraction are among the most reproducible. Rheumatic aetiology, which is more prevalent in Australian Indigenous populations and in patients born overseas in regions where rheumatic fever remains endemic, is also associated with greater structural remodelling and higher recurrence rates.

Operative factors include failure to perform a left atrial appendage ligation, use of a right-atrial-only lesion set in patients with longstanding arrhythmia, and limited surgeon experience with the chosen ablation technology. In Australian centres, the introduction of pulsed-field ablation catheters has prompted renewed interest in standardising lesion delivery, and ongoing collaboration through the Asia Pacific Heart Rhythm Society has helped align local training with international benchmarks. Recognising which patients carry a higher likelihood of recurrence allows tailored counselling before surgery, more intensive rhythm surveillance afterwards, and earlier consideration of hybrid ablation or repeat catheter ablation if atrial fibrillation returns.

Postoperative monitoring and detection

Detection of recurrent atrial fibrillation after the maze procedure is heavily dependent on the intensity and duration of monitoring. A single 12-lead electrocardiogram in the clinic will miss the majority of paroxysmal episodes, and even 24-hour Holter monitoring underestimates the true burden. Implantable loop recorders, used selectively in Australian surgical programmes, have yielded recurrence rates at 24 months that are substantially higher than those reported in studies relying on intermittent monitoring. For most patients, a pragmatic compromise involves ambulatory monitoring at three, six, and twelve months, with telehealth-supported event recorders used in rural and remote areas where access to cardiac services is limited.

Long QT and epilepsy are often cited in differential diagnosis during arrhythmic work-up, but the more common diagnostic pitfall in this cohort is misattributing postoperative fatigue, breathlessness, or palpitation to anxiety or to residual valve dysfunction. A structured pathway, ideally coordinated between the surgical unit, the treating cardiologist, and the patient's general practitioner, improves detection and ensures that imaging, rhythm monitoring, and laboratory assessment are not duplicated. In regional Queensland and Western Australia, where patients may travel hundreds of kilometres for follow-up, nurse-led arrhythmia clinics linked to tertiary centres have proven particularly valuable.

Therapeutic options for recurrent atrial fibrillation

When atrial fibrillation does recur after the maze procedure, management follows the same principles that guide any patient with symptomatic arrhythmia, but with some specific considerations. Rate control with beta-blockers or non-dihydropyridine calcium-channel blockers is usually well tolerated, though attention to postoperative blood pressure and conduction disease is warranted. Rhythm control with antiarrhythmic drugs such as sotalol or amiodarone is reasonable, particularly in the first six to twelve months when ongoing reverse remodelling may still favour sinus rhythm. In Australia, prescription of sotalol requires baseline electrolyte and renal review, and amiodarone initiation is typically supervised by a cardiologist given the long-term risk of thyroid, hepatic, and pulmonary toxicity.

Catheter-based ablation is a well-established option for patients with recurrent atrial fibrillation after surgical maze, and contemporary series report reasonable success rates, particularly when the original lesion set is mapped and gaps are targeted. Pulmonary vein isolation remains a cornerstone, but detailed mapping often reveals reconnections along the roof line or the mitral isthmus, and re-ablation of these regions can restore durable sinus rhythm. Reoperation for surgical ablation is rarely needed and carries substantially higher risk than catheter-based approaches. Anticoagulation decisions should follow standard CHA₂DS₂-VASc guidance, and in patients with a mechanical mitral valve replacement, warfarin remains the only option; non-vitamin K antagonist oral anticoagulants are contraindicated in this setting, a point of frequent confusion among junior medical staff and one that Australian prescribing software and the Pharmaceutical Benefits Scheme routinely flag.

For Australian clinicians and patients weighing the merits of the maze procedure at the time of mitral valve surgery, the practical message is that early success rates are high, but durable freedom from atrial fibrillation depends on lesion quality, patient selection, and structured long-term follow-up. Recurrent arrhythmia, when it occurs, is manageable with a combination of medical therapy, catheter ablation, and consistent anticoagulation, and outcomes are best when care is coordinated across the surgical, cardiology, and primary care teams. Explore the latest themed collections and original research at the journal homepage to stay informed as the evidence base continues to evolve.